Karyopharm Therapeutics major shareholder Sells $780,834 in Stock (KPTI)
Karyopharm Therapeutics (NASDAQ:KPTI) major shareholder Marcin Czernik sold 21,570 shares of Karyopharm Therapeutics stock on the open market in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $36.20, for a total value of $780,834.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Separately, analysts at Oppenheimer downgraded shares of Karyopharm Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $49.00.
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded down 3.14% during mid-day trading on Friday, hitting $33.60. The stock had a trading volume of 170,766 shares. Karyopharm Therapeutics has a 1-year low of $15.50 and a 1-year high of $47.98. The stock has a 50-day moving average of $39.29 and a 200-day moving average of $33.73. The company’s market cap is $1.000 billion.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.46) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.47) by $0.01. On average, analysts predict that Karyopharm Therapeutics will post $-2.01 earnings per share for the current fiscal year.
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.